Novo Nordisk sales beat estimates, but the story wasn’t Ozempic
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...
Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
pharmaphorum3d
Novo Nordisk once-weekly insulin clears first phase 3 test
For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying ... The lower injection frequency might also encourage ...
pharmaphorum4d
FDA rejects Novo Nordisk’s weekly basal insulin
Novo Nordisk ... a reservoir of insulin that gradually releases over time. It would allow patients with insulin-dependent diabetes to cover their basal insulin needs with one injection per ...
AOL5d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.
Morningstar6d
Novo Nordisk AS ADR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Drug Store News1d
FDA approves new indication for Novo Nordisk’s Ozempic
Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...
Medscape4d
A Review of 20 Years' Experience With the Novopen Family of Insulin Injection Devices
Clin Drug Invest. 2006;26(7):367-401.